Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Antibodies, Monoclonal"" wg kryterium: Temat


Starter badań:

Tytuł:
Methodology of the brodalumab assessment of hazards: a multicentre observational safety (BRAHMS) study.
Autorzy:
Reilev M; Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark .
Jensen PB; Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.
Ranch LS; Biostatistics and Pharmacoepidemiology, LEO Pharma A/S, Ballerup, Denmark.
Egeberg A; Department of dermatology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.
Furu K; Department of Chronic Diseases, Norwegian Institute of Public Helath, Oslo, Norway.
Gembert K; Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Institute, Stockholm, Sweden.
Hagg D; Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Institute, Stockholm, Sweden.
Haug U; Clinical Epidemiology, Leibniz-Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany.; Faculty of Human and Health Science, University of Bremen, Bremen, Germany.
Karlstad Ø; Department of Chronic Diseases, Norwegian Institute of Public Helath, Oslo, Norway.
Reutfors J; Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Institute, Stockholm, Sweden.
Schäfer W; Clinical Epidemiology, Leibniz-Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany.
Schwartz S; Clinical Epidemiology, Leibniz-Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany.
Smits E; PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.
Holthius E; PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.
Herings R; PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.; Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Trifirò G; Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Kirchmayer U; Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.
Rosa AC; Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.
Belleudi V; Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.
Gini R; Epidemiology Unit, Agenzia regionale di sanità della Toscana, Florence, Italy.
Støvring H; Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.
Hallas J; Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.
Pokaż więcej
Źródło:
BMJ open [BMJ Open] 2023 Feb 01; Vol. 13 (2), pp. e066057. Date of Electronic Publication: 2023 Feb 01.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Antibodies, Monoclonal, Humanized*/adverse effects
Psoriasis*/drug therapy
Humans ; Antibodies, Monoclonal/therapeutic use ; Treatment Outcome ; Severity of Illness Index
Czasopismo naukowe
Tytuł:
Göttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation.
Autorzy:
Grabowski T; Polpharma Biologics SA, Trzy lipy 3, 80-172 Gdańsk, Poland; Department of Inorganic Chemistry, Medical University of Gdańsk, 80-416 Gdansk, Poland. Electronic address: .
Derlacz R; Polpharma Biologics SA, Trzy lipy 3, 80-172 Gdańsk, Poland. Electronic address: .
Burmańczuk A; Sub-Department of Pharmacology, Toxicology and Environmental Protection, Faculty of Veterinary Medicine, University of Life Sciences, Akademicka 12, 20-033 Lublin, Poland. Electronic address: .
Pokaż więcej
Źródło:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2022 Dec; Vol. 156, pp. 113926. Date of Electronic Publication: 2022 Oct 26.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal, Humanized*/therapeutic use
Integrin alpha4*
Female ; Animals ; Swine ; Natalizumab/pharmacology ; Natalizumab/therapeutic use ; Swine, Miniature ; Antibodies, Monoclonal/therapeutic use
Czasopismo naukowe
Tytuł:
Antibody-dependent cell-mediated cytotoxicity using T cells with NK-like phenotype in combination with avelumab, an anti-PD-L1 antibody.
Autorzy:
Liu D; Department of Radiology, The First Hospital of Tsinghua University, Beijing, China.
Hu Y; Department of Interventional Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Wei J; Department of Interventional Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Zhang W; Department of Oncology, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Piao C; Department of Oncology, Beijing Anzhen Hospital Affiliated to the Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China.
Lu Y; Department of Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts, USA.
Wang Y; Department of Oncology, Beijing Biohealthcare Biotechnology Co., Ltd, Bejing, China.
Liu J; Department of Oncology, Beijing Biohealthcare Biotechnology Co., Ltd, Bejing, China.
Lu X; Department of Oncology, Beijing Biohealthcare Biotechnology Co., Ltd, Bejing, China.
Pokaż więcej
Źródło:
Immunology [Immunology] 2022 Oct; Vol. 167 (2), pp. 212-220. Date of Electronic Publication: 2022 Aug 15.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal*/genetics
Antibodies, Monoclonal*/pharmacology
Antibodies, Monoclonal*/therapeutic use
T-Lymphocytes*/metabolism
Animals ; Antibodies, Monoclonal, Humanized ; B7-H1 Antigen ; Cell Line, Tumor ; Granzymes/genetics ; Humans ; Killer Cells, Natural ; Mice ; Perforin/genetics ; Phenotype
Czasopismo naukowe
Tytuł:
Advancing humanized monoclonal antibody for counteracting fentanyl toxicity towards clinical development.
Autorzy:
Hicks D; Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA.
Baehr C; Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA.
Silva-Ortiz P; Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA.
Khaimraj A; Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA.
Luengas D; Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA.
Hamid FA; Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA.
Pravetoni M; Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA.; Center for Immunology, University of Minnesota, Minneapolis, MN, USA.; School of Medicine, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło:
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2022 Nov 30; Vol. 18 (6), pp. 2122507. Date of Electronic Publication: 2022 Oct 04.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal, Humanized*/therapeutic use
Fentanyl*/immunology
Fentanyl*/toxicity
Narcotic Antagonists*/chemistry
Narcotic Antagonists*/immunology
Animals ; Humans ; Mice ; Rats ; Antibodies, Monoclonal/therapeutic use ; Complement System Proteins
Czasopismo naukowe
Tytuł:
Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.
Autorzy:
Augustin M; Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sator PG; Department of Dermatology, Municipal Hospital Hietzing, Vienna, Austria.
von Kiedrowski R; Company for Medical Study & Service Selters (CMS3) GmbH, Selters, Germany.
Conrad C; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Rigopoulos D; Dermatology and Venerology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Romanelli M; Dermatology Department, University of Pisa, Pisa, Italy.
Ghislain PD; Dermatology, Cliniques Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Torres T; Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal.
Ioannides D; First Department of Dermatology and Venereology, School of Medicine, Aristotle University, Thessaloniki, Greece.
Aassi M; Novartis Pharma AG, Basel, Switzerland.
Schulz B; Novartis Pharma AG, Basel, Switzerland.
Jagiello P; Novartis Pharma AG, Basel, Switzerland.
Pokaż więcej
Corporate Authors:
SERENA study group
Źródło:
Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2022 Oct; Vol. 36 (10), pp. 1796-1804. Date of Electronic Publication: 2022 Jul 04.
Typ publikacji:
Journal Article; Observational Study
MeSH Terms:
Antibodies, Monoclonal*/adverse effects
Psoriasis*/chemically induced
Psoriasis*/drug therapy
Adult ; Antibodies, Monoclonal, Humanized/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Physiologically-based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency.
Autorzy:
Salerno SN; Gilead Sciences, Inc., Foster City, California, USA.
Deng R; Gilead Sciences, Inc., Foster City, California, USA.; R&D Q-Pharm Consulting LLC, Pleasanton, California, USA.
Kakkar T; Gilead Sciences, Inc., Foster City, California, USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2022 Oct; Vol. 11 (10), pp. 1316-1327. Date of Electronic Publication: 2022 Aug 08.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal*
Immunoglobulins, Intravenous*/therapeutic use
Aged ; Animals ; Antibodies, Monoclonal, Humanized ; Child ; Humans ; Integrins ; Mice ; Protein-Tyrosine Kinases ; Rats
Czasopismo naukowe
Tytuł:
Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis.
Autorzy:
Ruiz-Villaverde R; Dermatology Department, Hospital Universitario San Cecilio, Granada, Spain.
Rodriguez-Fernandez-Freire L; Dermatology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain.
Armario-Hita JC; Dermatology Department, Hospital Universitario Puerto Real, Cádiz, Spain.
Pérez-Gil A; Dermatology Department, Hospital Universitario Virgen de Valme, Sevilla, Spain.
Chinchay FV; Dermatology Department, Hospital Quirón Salud Sagrado Corazón, Sevilla, Spain.
Galán-Gutiérrez M; Dermatology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.
Pokaż więcej
Źródło:
Dermatologic therapy [Dermatol Ther] 2022 Oct; Vol. 35 (10), pp. e15760. Date of Electronic Publication: 2022 Aug 15.
Typ publikacji:
Journal Article; Multicenter Study; Observational Study
MeSH Terms:
Antibodies, Monoclonal*/adverse effects
Psoriasis*/chemically induced
Psoriasis*/diagnosis
Psoriasis*/drug therapy
Antibodies, Monoclonal, Humanized ; Humans ; Pruritus/drug therapy ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome ; Tumor Necrosis Factor Inhibitors
Czasopismo naukowe
Tytuł:
Multicolor fluorescence activated cell sorting to generate humanized monoclonal antibody binding seven subtypes of BoNT/F.
Autorzy:
Fan Y; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.
Sun Z; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.
Conrad F; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.
Wen W; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.
Zhao L; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.
Lou J; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.
Zhou Y; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.
Farr-Jones S; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.
Marks JD; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 Sep 01; Vol. 17 (9), pp. e0273512. Date of Electronic Publication: 2022 Sep 01 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Antibodies, Monoclonal, Humanized*/chemistry
Botulinum Toxins*/immunology
Flow Cytometry*/methods
Animals ; Antibodies, Monoclonal/chemistry ; Cross Reactions ; HEK293 Cells ; Humans ; Mice ; Single-Chain Antibodies/chemistry
Czasopismo naukowe
Tytuł:
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting.
Autorzy:
Megna M; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Potestio L; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Camela E; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Fabbrocini G; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Ruggiero A; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Pokaż więcej
Źródło:
Dermatologic therapy [Dermatol Ther] 2022 Sep; Vol. 35 (9), pp. e15667. Date of Electronic Publication: 2022 Jul 11.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal*/therapeutic use
Psoriasis*/chemically induced
Psoriasis*/diagnosis
Psoriasis*/drug therapy
Antibodies, Monoclonal, Humanized ; Humans ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis.
Autorzy:
Zappulo E; Infectious Diseases Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, S. Pansini street, number 5, Naples 80131, Italy.
Buonomo AR; Infectious Diseases Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, S. Pansini street, number 5, Naples 80131, Italy. Electronic address: .
Moccia M; Multiple Sclerosis Clinical Care and Research Center, Department of Neuroscience, University of Naples Federico II, S. Pansini street, number 5, Naples 80131, Italy.
Pinchera B; Infectious Diseases Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, S. Pansini street, number 5, Naples 80131, Italy.
Villari R; Infectious Diseases Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, S. Pansini street, number 5, Naples 80131, Italy.
Petracca M; Multiple Sclerosis Clinical Care and Research Center, Department of Neuroscience, University of Naples Federico II, S. Pansini street, number 5, Naples 80131, Italy; Department of Human Neurosciences, Sapienza University, Rome, Italy.
Lanzillo R; Multiple Sclerosis Clinical Care and Research Center, Department of Neuroscience, University of Naples Federico II, S. Pansini street, number 5, Naples 80131, Italy.
Scotto R; Infectious Diseases Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, S. Pansini street, number 5, Naples 80131, Italy.
Carotenuto A; Multiple Sclerosis Clinical Care and Research Center, Department of Neuroscience, University of Naples Federico II, S. Pansini street, number 5, Naples 80131, Italy.
Viceconte G; Infectious Diseases Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, S. Pansini street, number 5, Naples 80131, Italy.
Schiano Moriello N; Infectious Diseases Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, S. Pansini street, number 5, Naples 80131, Italy.
Bruno L; Infectious Diseases Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, S. Pansini street, number 5, Naples 80131, Italy.
Gentile I; Infectious Diseases Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, S. Pansini street, number 5, Naples 80131, Italy.
Brescia Morra V; Multiple Sclerosis Clinical Care and Research Center, Department of Neuroscience, University of Naples Federico II, S. Pansini street, number 5, Naples 80131, Italy.
Pokaż więcej
Źródło:
Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2022 Jul; Vol. 63, pp. 103814. Date of Electronic Publication: 2022 Apr 21.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal*/adverse effects
Antibodies, Monoclonal*/therapeutic use
Antineoplastic Agents, Immunological*/adverse effects
Antineoplastic Agents, Immunological*/therapeutic use
Infections*/chemically induced
Infections*/diagnosis
Multiple Sclerosis*/drug therapy
Alemtuzumab/adverse effects ; Alemtuzumab/therapeutic use ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antigens, CD20 ; CD52 Antigen ; Humans ; Middle Aged ; Prospective Studies ; Referral and Consultation ; Retrospective Studies ; Rituximab/adverse effects ; Rituximab/therapeutic use
Czasopismo naukowe
Tytuł:
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.
Autorzy:
Gan HK; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia. .; School of Cancer Medicine, La Trobe University, Melbourne, Australia. .; Department of Medical Oncology, Austin Health, Melbourne, Australia. .
Parakh S; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Medical Oncology, Austin Health, Melbourne, Australia.
Lee FT; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
Tebbutt NC; Department of Medical Oncology, Austin Health, Melbourne, Australia.
Ameratunga M; Department of Medical Oncology, Austin Health, Melbourne, Australia.
Lee ST; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.; Faculty of Medicine, University of Melbourne, Melbourne, Australia.
O'Keefe GJ; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.
Gong SJ; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.
Vanrenen C; Department of Medical Oncology, Austin Health, Melbourne, Australia.
Caine J; Department of Medical Oncology, Austin Health, Melbourne, Australia.
Giovannetti M; Ludwig Cancer Research, New York, NY, USA.
Murone C; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
Scott FE; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Guo N; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
Burvenich IJG; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Paine C; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.
Macri MJ; Ludwig Cancer Research, New York, NY, USA.
Kotsuma M; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.
Senaldi G; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.
Venhaus R; Ludwig Cancer Research, New York, NY, USA.
Scott AM; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.; Faculty of Medicine, University of Melbourne, Melbourne, Australia.
Pokaż więcej
Źródło:
Investigational new drugs [Invest New Drugs] 2022 Aug; Vol. 40 (4), pp. 747-755. Date of Electronic Publication: 2022 Apr 11.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal, Humanized*/pharmacokinetics
Antibodies, Monoclonal, Humanized*/therapeutic use
Antineoplastic Agents, Immunological*/pharmacokinetics
Antineoplastic Agents, Immunological*/therapeutic use
Neoplasms*/diagnostic imaging
Neoplasms*/drug therapy
Aged ; Aged, 80 and over ; Antibodies, Monoclonal ; Antineoplastic Agents ; Ephrin-A2/immunology ; Humans ; Male ; Middle Aged ; Receptor, EphA2/drug effects ; Tissue Distribution
Czasopismo naukowe
Tytuł:
Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses.
Autorzy:
Woopen C; Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus Dresden, Technical University of Dresden, Dresden, Germany.
Konofalska U; Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus Dresden, Technical University of Dresden, Dresden, Germany.
Akgün K; Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus Dresden, Technical University of Dresden, Dresden, Germany.
Ziemssen T; Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus Dresden, Technical University of Dresden, Dresden, Germany.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2022 Jul 25; Vol. 13, pp. 897748. Date of Electronic Publication: 2022 Jul 25 (Print Publication: 2022).
Typ publikacji:
Case Reports
MeSH Terms:
Antibodies, Monoclonal, Humanized*/administration & dosage
Antibodies, Monoclonal, Humanized*/adverse effects
COVID-19*/prevention & control
Multiple Sclerosis*/drug therapy
Pre-Exposure Prophylaxis*
Antibodies, Monoclonal ; Antibodies, Neutralizing ; Antibodies, Viral ; Humans ; SARS-CoV-2 ; Sphingosine-1-Phosphate Receptors ; Vaccination
SCR Organism:
SARS-CoV-2 variants
Raport
Tytuł:
Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series.
Autorzy:
Ruiz-Villaverde R; Dermatology Department, Hospital Universitario San Cecilio, Granada, Spain.
Rodriguez-Fernandez-Freire L; Dermatology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain.
Armario-Hita JC; Dermatology Department, Hospital Universitario Puerto Real, Cádiz, Spain.
Pérez-Gil A; Dermatology Department, Hospital Universitario Virgen de Valme, Sevilla, Spain.
Galán-Gutiérrez M; Dermatology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.
Pokaż więcej
Źródło:
International journal of dermatology [Int J Dermatol] 2022 Aug; Vol. 61 (8), pp. 1029-1033. Date of Electronic Publication: 2021 Nov 03.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal*/therapeutic use
Psoriasis*/chemically induced
Psoriasis*/drug therapy
Antibodies, Monoclonal, Humanized ; Humans ; Pruritus/chemically induced ; Pruritus/etiology ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł:
A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis.
Autorzy:
Zhang C; Department of Dermatology, Peking University Third Hospital, Beijing, People's Republic of China.
Yan K; Department of Dermatology, Huashan Hospital Affiliated to Fudan University, Shanghai, People's Republic of China.
Diao Q; Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, People's Republic of China.
Guo Q; Department of Dermatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
Jin H; Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Yang S; Institute of Dermatology and Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.
Chen X; Department of Dermatology, Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Lei T; Department of Dermatology, Renmin Hospital of Wuhan University/Hubei General Hospital, Wuhan, People's Republic of China.
Wu J; Department of Dermatology, Changhai Hospital of Shanghai, Shanghai, People's Republic of China.
Yu H; Department of Dermatology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China.
Zheng M; Department of Dermatology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Gao X; Department of Dermatology, The 1st Hospital of China Medical University, Shenyang, People's Republic of China.
Sinclair R; Sinclair Dermatology, East Melbourne, Australia.
Zhu Y; Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, People's Republic of China.
Xu Q; Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, People's Republic of China.
Xu J; Department of Dermatology, Huashan Hospital Affiliated to Fudan University, Shanghai, People's Republic of China. Electronic address: .
Pokaż więcej
Źródło:
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2022 Jul; Vol. 87 (1), pp. 95-102. Date of Electronic Publication: 2022 Jan 10.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal, Humanized*/adverse effects
Psoriasis*/chemically induced
Psoriasis*/diagnosis
Psoriasis*/drug therapy
Antibodies, Monoclonal/adverse effects ; Double-Blind Method ; Humans ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma.
Autorzy:
Kotani N; Genentech Inc., South San Francisco, California, USA.; Chugai Pharmaceutical Co. Ltd., Tokyo, Japan.
Dolton M; Genentech Inc., South San Francisco, California, USA.
Svensson RJ; Pharmetheus, Uppsala, Sweden.
Ribbing J; Pharmetheus, Uppsala, Sweden.
Friberg LE; Pharmetheus, Uppsala, Sweden.; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Vadhavkar S; Genentech Inc., South San Francisco, California, USA.
Cheung D; Genentech Inc., South San Francisco, California, USA.
Staton T; Genentech Inc., South San Francisco, California, USA.
Sperinde G; Genentech Inc., South San Francisco, California, USA.
Jin J; Genentech Inc., South San Francisco, California, USA.
Putnam WS; Genentech Inc., South San Francisco, California, USA.
Quartino A; Genentech Inc., South San Francisco, California, USA.
Pokaż więcej
Źródło:
Journal of clinical pharmacology [J Clin Pharmacol] 2022 Jul; Vol. 62 (7), pp. 905-917. Date of Electronic Publication: 2022 Feb 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal, Humanized*/pharmacokinetics
Asthma*/drug therapy
Antibodies, Monoclonal/pharmacokinetics ; Body Weight ; Clinical Trials, Phase II as Topic ; Humans
Czasopismo naukowe
Tytuł:
Avelumab Dose Selection for Clinical Studies in Pediatric Patients with Solid Tumors.
Autorzy:
Vugmeyster Y; EMD Serono Research & Development Institute, Inc. (an affiliate of Merck KGaA), Billerica, MA, USA.
Grisic AM; Merck Healthcare KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Brockhaus B; Merck Healthcare KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Rueckert P; Merck Healthcare KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Ruisi M; EMD Serono Research & Development Institute, Inc. (an affiliate of Merck KGaA), Billerica, MA, USA.
Dai H; EMD Serono Research & Development Institute, Inc. (an affiliate of Merck KGaA), Billerica, MA, USA.
Khandelwal A; Merck Healthcare KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany. .
Pokaż więcej
Źródło:
Clinical pharmacokinetics [Clin Pharmacokinet] 2022 Jul; Vol. 61 (7), pp. 985-995. Date of Electronic Publication: 2022 Apr 29.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal*/pharmacokinetics
Neoplasms*/drug therapy
Adult ; Antibodies, Monoclonal, Humanized ; Body Weight ; Child ; Humans
Czasopismo naukowe
Tytuł:
Targeted B-domain deletion restores F8 function in human endothelial cells and mice.
Autorzy:
Hu Z; Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, 410078, China.
Li Z; Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, 410078, China.
Wu Y; Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, 410078, China.
Zhao J; Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, 410078, China.
Wu L; Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, 410078, China.
Zhou M; Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, 410078, China. .
Liang D; Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, 410078, China. .
Pokaż więcej
Źródło:
Signal transduction and targeted therapy [Signal Transduct Target Ther] 2022 Jun 20; Vol. 7 (1), pp. 189. Date of Electronic Publication: 2022 Jun 20.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal*
Endothelial Cells*
Animals ; Antibodies, Monoclonal, Humanized ; Humans ; Mice
Raport
Tytuł:
Direct CNS administration of rituximab and epratuzumab in a pediatric patient with relapsed refractory CNS B-cell acute lymphoblastic leukemia.
Autorzy:
McClane J; Department of Pediatrics, Brown University and Hasbro Children's Hospital, Providence, Rhode Island, USA.
Chawla A; Division of Hematology Oncology, Department of Pediatrics, Brown University and Hasbro Children's Hospital, Providence, Rhode Island, USA.
Welch JJG; Division of Hematology Oncology, Department of Pediatrics, Brown University and Hasbro Children's Hospital, Providence, Rhode Island, USA.
Pokaż więcej
Źródło:
Pediatric blood & cancer [Pediatr Blood Cancer] 2022 Jun; Vol. 69 (6), pp. e29664. Date of Electronic Publication: 2022 Mar 16.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Antibodies, Monoclonal, Humanized*/therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/therapy
Adolescent ; Antibodies, Monoclonal/therapeutic use ; Child ; Humans ; Rituximab/therapeutic use
Czasopismo naukowe
Tytuł:
A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.
Autorzy:
Medina-Catalán D; Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Carrer de Sant Quintí, 89, 08041, Barcelona, Spain.
Riera P; Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Carrer de Sant Quintí, 89, 08041, Barcelona, Spain.; U705, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Barcelona, Spain.
Pagès-Puigdemont N; Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Carrer de Sant Quintí, 89, 08041, Barcelona, Spain. .
Masip M; Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Carrer de Sant Quintí, 89, 08041, Barcelona, Spain.
López-Ferrer A; Dermatology Department, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
Vilarrasa E; Dermatology Department, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
Puig L; Dermatology Department, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
Pokaż więcej
Źródło:
International journal of clinical pharmacy [Int J Clin Pharm] 2022 Jun; Vol. 44 (3), pp. 725-730. Date of Electronic Publication: 2022 Apr 05.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal*/adverse effects
Psoriasis*/diagnosis
Psoriasis*/drug therapy
Antibodies, Monoclonal, Humanized ; Biological Therapy ; Cohort Studies ; Humans ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Autorzy:
Djebbari F; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Poynton M; Royal Berkshire Hospital, Reading, UK.
Sangha G; Milton Keynes Hospital, Milton Keynes, UK.
Anderson L; Royal United Hospital Bath, Bath, UK.
Maddams R; Poole Hospital, Poole, UK.
Eyre TA; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Vallance G; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Basu S; The Royal Wolverhampton NHS Trust, Wolverhampton, UK.; Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK.; West Midlands Research Consortium (WMRC), West Midlands, UK.
Ramasamy K; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2022 Dec; Vol. 27 (1), pp. 204-207.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Dexamethasone/*therapeutic use
Multiple Myeloma/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Thalidomide/*analogs & derivatives
ADP-ribosyl Cyclase 1/antagonists & inhibitors ; Aged ; Antibodies, Monoclonal/therapeutic use ; Female ; Humans ; Male ; Membrane Glycoproteins/antagonists & inhibitors ; Middle Aged ; Thalidomide/therapeutic use ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz